Literature DB >> 10606966

Molecular determinants of polyreactive antibody binding: HCDR3 and cyclic peptides.

Y J Deng1, A L Notkins.   

Abstract

Human monoclonal antibody 63 (mAb63) is an IgM/lambda polyreactive antibody that binds to multiple self and non-self antigens. The molecular basis of polyreactivity is still unclear. The present study was initiated to prepare a recombinant Fab of mAb63 and use it to study the determinants involved in polyreactivity. The baculovirus system was employed to express large amounts of mAb63 Fab in Sf9 cells. Our experiments showed that infected Sf9 cells secreted a soluble 50-kD Fab heterodimer that bound to multiple self and non-self antigens. The antigen-binding activity of mAb63 Fab was inhibited by both homologous and heterologous antigens. To study in more detail the molecular determinants involved in polyreactivity, the heavy chain complementarity-determining region 3 (HCDR3), which is known to play a key role in the binding of monoreactive antibodies to antigens, was subjected to site-directed mutagenesis. A single substitution, alanine for arginine, at position 100A resulted in complete loss of antigen-binding activity. The 19 amino acids comprising the HCDR3 of mAb63 were then synthesized and a cyclic peptide prepared. The cyclic peptide showed the same antigen-binding pattern as the parental mAb63 and the recombinant mAb63 Fab. A five amino acid motif (RFLEW), present in the HCDR3 of mAb63, was found by searching the GenBank in three of 50 other human polyreactive antibodies, but in none of nearly 2500 human antibodies thought to be monoreactive. It is concluded that HCDR3 plays a major role in polyreactivity and that in some cases cyclic peptides comprising the HCDR3, by themselves, may be polyreactive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10606966      PMCID: PMC1905533          DOI: 10.1046/j.1365-2249.2000.01096.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

1.  Antigen-binding B cells and polyreactive antibodies.

Authors:  Z J Chen; J Wheeler; A L Notkins
Journal:  Eur J Immunol       Date:  1995-02       Impact factor: 5.532

2.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution.

Authors:  A G Amit; R A Mariuzza; S E Phillips; R J Poljak
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

3.  Polyreactive IgM antibodies in the circulation are masked by antigen binding.

Authors:  G Sigounas; N Kolaitis; E Monell-Torrens; A L Notkins
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

4.  Human monoclonal autoantibodies that react with multiple endocrine organs.

Authors:  J Satoh; B S Prabhakar; M V Haspel; F Ginsberg-Fellner; A L Notkins
Journal:  N Engl J Med       Date:  1983-07-28       Impact factor: 91.245

5.  Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset.

Authors:  P Casali; S E Burastero; M Nakamura; G Inghirami; A L Notkins
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

6.  The three dimensional structure of a combining region-ligand complex of immunoglobulin NEW at 3.5-A resolution.

Authors:  L M Amzel; R J Poljak; F Saul; J M Varga; F F Richards
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

7.  Murine hybridomas secreting natural monoclonal antibodies reacting with self antigens.

Authors:  G Dighiero; P Lymberi; J C Mazié; S Rouyre; G S Butler-Browne; R G Whalen; S Avrameas
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

8.  Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors.

Authors:  R Crouzier; T Martin; J L Pasquali
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

9.  Human polyreactive and monoreactive antibodies: effect of glycosylation on antigen binding.

Authors:  G Donadel; A Calabro; G Sigounas; V C Hascall; A L Notkins; N Harindranath
Journal:  Glycobiology       Date:  1994-08       Impact factor: 4.313

10.  Multiple organ-reactive monoclonal autoantibodies.

Authors:  M V Haspel; T Onodera; B S Prabhakar; P R McClintock; K Essani; U R Ray; S Yagihashi; A L Notkins
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

View more
  5 in total

1.  The natural antibody repertoire of sharks and humans recognizes the potential universe of antigens.

Authors:  Miranda K Adelman; Samuel F Schluter; John J Marchalonis
Journal:  Protein J       Date:  2004-02       Impact factor: 2.371

2.  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Authors:  Renee C Tschumper; Susan M Geyer; Megan E Campbell; Neil E Kay; Tait D Shanafelt; Clive S Zent; Grzegorz S Nowakowski; Timothy G Call; Gordon W Dewald; Diane F Jelinek
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

3.  Uncovering temporospatial sensitive TBI targeting strategies via in vivo phage display.

Authors:  Briana I Martinez; Gergey Alzaem Mousa; Kiera Fleck; Tara MacCulloch; Chris W Diehnelt; Nicholas Stephanopoulos; Sarah E Stabenfeldt
Journal:  Sci Adv       Date:  2022-07-22       Impact factor: 14.957

Review 4.  Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Authors:  Alan Berezov; Mark I Greene; Ramachandran Murali
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

5.  Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses.

Authors:  Jenna J Guthmiller; Linda Yu-Ling Lan; Monica L Fernández-Quintero; Julianna Han; Henry A Utset; Dalia J Bitar; Natalie J Hamel; Olivia Stovicek; Lei Li; Micah Tepora; Carole Henry; Karlynn E Neu; Haley L Dugan; Marta T Borowska; Yao-Qing Chen; Sean T H Liu; Christopher T Stamper; Nai-Ying Zheng; Min Huang; Anna-Karin E Palm; Adolfo García-Sastre; Raffael Nachbagauer; Peter Palese; Lynda Coughlan; Florian Krammer; Andrew B Ward; Klaus R Liedl; Patrick C Wilson
Journal:  Immunity       Date:  2020-10-22       Impact factor: 31.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.